PL3102212T3 - Inhibitor białka przenoszącego estry cholesterolu (CETP) i kompozycje farmaceutyczne zawierające taki inhibitor do stosowania w leczeniu chorób sercowo-naczyniowych lub zapobieganiu im. - Google Patents

Inhibitor białka przenoszącego estry cholesterolu (CETP) i kompozycje farmaceutyczne zawierające taki inhibitor do stosowania w leczeniu chorób sercowo-naczyniowych lub zapobieganiu im.

Info

Publication number
PL3102212T3
PL3102212T3 PL14705225T PL14705225T PL3102212T3 PL 3102212 T3 PL3102212 T3 PL 3102212T3 PL 14705225 T PL14705225 T PL 14705225T PL 14705225 T PL14705225 T PL 14705225T PL 3102212 T3 PL3102212 T3 PL 3102212T3
Authority
PL
Poland
Prior art keywords
inhibitor
cetp
prevention
treatment
pharmaceutical compositions
Prior art date
Application number
PL14705225T
Other languages
English (en)
Inventor
John Ford
Patrick ROUND
John Kastelein
Atsuhiro KAWAGUCHI
Koichi TOMIYASU
Kozo Oka
Original Assignee
Dezima Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dezima Pharma B V filed Critical Dezima Pharma B V
Publication of PL3102212T3 publication Critical patent/PL3102212T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL14705225T 2014-02-05 2014-02-05 Inhibitor białka przenoszącego estry cholesterolu (CETP) i kompozycje farmaceutyczne zawierające taki inhibitor do stosowania w leczeniu chorób sercowo-naczyniowych lub zapobieganiu im. PL3102212T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2014/050068 WO2015119495A1 (en) 2014-02-05 2014-02-05 Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
EP14705225.2A EP3102212B1 (en) 2014-02-05 2014-02-05 Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases

Publications (1)

Publication Number Publication Date
PL3102212T3 true PL3102212T3 (pl) 2019-05-31

Family

ID=50116144

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14705225T PL3102212T3 (pl) 2014-02-05 2014-02-05 Inhibitor białka przenoszącego estry cholesterolu (CETP) i kompozycje farmaceutyczne zawierające taki inhibitor do stosowania w leczeniu chorób sercowo-naczyniowych lub zapobieganiu im.

Country Status (33)

Country Link
US (6) US10653692B2 (pl)
EP (1) EP3102212B1 (pl)
JP (1) JP6263271B2 (pl)
KR (1) KR101967970B1 (pl)
CN (8) CN112755031A (pl)
AP (1) AP2016009359A0 (pl)
AR (1) AR099299A1 (pl)
AU (1) AU2014381733B2 (pl)
BR (1) BR112016018077A8 (pl)
CA (1) CA2938718C (pl)
CR (1) CR20160353A (pl)
CY (1) CY1121707T1 (pl)
DK (1) DK3102212T3 (pl)
EA (1) EA032689B1 (pl)
ES (1) ES2710104T3 (pl)
HR (1) HRP20190211T1 (pl)
HU (1) HUE042932T2 (pl)
IL (1) IL247037A (pl)
LT (1) LT3102212T (pl)
MA (1) MA39319A1 (pl)
ME (1) ME03295B (pl)
MX (1) MX369471B (pl)
PH (1) PH12016501548B1 (pl)
PL (1) PL3102212T3 (pl)
PT (1) PT3102212T (pl)
RS (1) RS58329B1 (pl)
SG (1) SG11201605956RA (pl)
SI (1) SI3102212T1 (pl)
SM (1) SMT201900052T1 (pl)
TW (1) TWI651086B (pl)
UA (1) UA120922C2 (pl)
WO (1) WO2015119495A1 (pl)
ZA (1) ZA201605490B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605956RA (en) 2014-02-05 2016-08-30 Dezima Pharma B V Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
EP3185869A1 (en) * 2014-08-28 2017-07-05 Dezima Pharma B.V. PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG CoA REDUCTASE INHIBITORS
EP4294387A1 (en) * 2021-02-18 2023-12-27 NewAmsterdam Pharma B.V. Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia
EP4125911B1 (en) * 2021-03-05 2024-04-24 NewAmsterdam Pharma B.V. Obicetrapib for treatment of dementias
PE20251749A1 (es) 2022-07-05 2025-07-09 Newamsterdam Pharma B V Sales de obicetrapib y procesos para su fabricacion y productos intermedios de estos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
JP4531027B2 (ja) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
CN101553221A (zh) * 2006-10-10 2009-10-07 瑞莱恩特医药品有限公司 用于降低APO-B水平的抑制素和ω-3脂肪酸
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
SG11201605956RA (en) * 2014-02-05 2016-08-30 Dezima Pharma B V Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
EP3185869A1 (en) * 2014-08-28 2017-07-05 Dezima Pharma B.V. PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG CoA REDUCTASE INHIBITORS

Also Published As

Publication number Publication date
US20260007669A1 (en) 2026-01-08
BR112016018077A2 (pt) 2017-08-08
ES2710104T3 (es) 2019-04-23
EA201691572A1 (ru) 2016-12-30
US20200230138A1 (en) 2020-07-23
US12186315B2 (en) 2025-01-07
US20250228852A1 (en) 2025-07-17
ME03295B (me) 2019-07-20
CN119499252A (zh) 2025-02-25
AU2014381733B2 (en) 2020-09-03
UA120922C2 (uk) 2020-03-10
MX369471B (es) 2019-11-08
SI3102212T1 (sl) 2019-03-29
KR101967970B1 (ko) 2019-04-10
EP3102212A1 (en) 2016-12-14
KR20160146664A (ko) 2016-12-21
HRP20190211T1 (hr) 2019-04-05
CN121818650A (zh) 2026-04-10
JP2017505333A (ja) 2017-02-16
PH12016501548A1 (en) 2016-10-03
CR20160353A (es) 2017-06-23
WO2015119495A1 (en) 2015-08-13
NZ723645A (en) 2020-09-25
AR099299A1 (es) 2016-07-13
US11642344B2 (en) 2023-05-09
CN113332288B (zh) 2026-03-24
CN113332287A (zh) 2021-09-03
DK3102212T3 (en) 2019-02-11
AP2016009359A0 (en) 2016-08-31
US20210228580A1 (en) 2021-07-29
TWI651086B (zh) 2019-02-21
CA2938718A1 (en) 2015-08-13
BR112016018077A8 (pt) 2020-06-23
MX2016010212A (es) 2017-08-10
CN110721187A (zh) 2020-01-24
US20170182048A1 (en) 2017-06-29
CY1121707T1 (el) 2020-07-31
ZA201605490B (en) 2018-05-30
SG11201605956RA (en) 2016-08-30
AU2014381733A1 (en) 2016-08-18
CA2938718C (en) 2022-10-18
LT3102212T (lt) 2019-02-25
CN112755031A (zh) 2021-05-07
EA032689B1 (ru) 2019-07-31
CN113332288A (zh) 2021-09-03
IL247037A (en) 2017-01-31
HUE042932T2 (hu) 2019-07-29
US20240024315A1 (en) 2024-01-25
JP6263271B2 (ja) 2018-01-17
RS58329B1 (sr) 2019-03-29
CN121910736A (zh) 2026-04-24
PT3102212T (pt) 2019-02-06
US11013742B2 (en) 2021-05-25
TW201613597A (en) 2016-04-16
SMT201900052T1 (it) 2019-02-28
US10653692B2 (en) 2020-05-19
MA39319A1 (fr) 2017-07-31
EP3102212B1 (en) 2018-11-07
CN106232121A (zh) 2016-12-14
PH12016501548B1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
CY2022008I1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου ηαο1 (οξειδαση υδροξυοξεος 1 (γλυκολικη οξειδαση)
IL252596A0 (en) History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
ES2856150T5 (en) Use of an inverse transcriptase inhibitor for the treatment and prevention of degenerative diseases
IL252683A0 (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
ZA201605490B (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
IL248210A0 (en) Methods and preparations for the treatment of blood vessel malformations
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
EP3161490A4 (en) COMPOSITIONS AND METHODS FOR DETECTING HUMAN PEGIVIRUS 2 (HPgV-2)
PT3197556T (pt) Composição para a prevenção e/ou tratamento de sintomas de alergia
BR112017007754A2 (pt) composições de ácido graxo monoinsaturado e uso para o tratamento de aterosclerose.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
SMT202100490T1 (it) Composizione comprendente geraniolo e zenzero secco per l'uso nel trattamento della sindrome del colon irritabile
EP3225237A4 (en) Fatty acid amides for the prevention and/or treatment of steatohepatitis
IL266659B (en) fgfr4 inhibitor, a pharmaceutical preparation containing it and its use
PL2926867T3 (pl) Kompozycje peelingujące zawierające kwas trichlorooctowy (TCA) i fenol do zmniejszania piekącego bólu wywołanego przez TCA
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
ES3066523T3 (en) Pharmaceutical composition comprising vitamin k2 for use in the treatment or prevention of melanoma
EP3104940A4 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same
IL243402A0 (en) Methods for identifying preparations for use in the treatment of heart diseases and the use of preparations for the treatment of these diseases
HK1236834A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
HK1231001A1 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
TH1501006461A (th) อนุพันธ์ของโดลาสแททิน 10 และออริสแททิน (Derivatives of dolastatin 10 and auristatins)